GEN Exclusives

More »

GEN News Highlights

More »
Apr 3, 2007

FSMA and Paratek Pharmaceuticals Continue Spinal Muscular Atrophy Partnership

  • Families of Spinal Muscular Atrophy (FSMA) and Paratek Pharmaceuticals extended their R&D collaboration to develop a drug candidate for the treatment of spinal muscular atrophy. 

    The collaboration is focused on optimizing and advancing into the clinic a novel small molecule within Paratek's library derived from the tetracycline class of compounds.

    "We are excited by the progress in our program with Paratek, which in the past year has demonstrated positive results in early cell models of this disease," remarks Kenneth Hobby, executive director of FSMA.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using Pet Dogs with Cancer in Preclinical Trials

Do you agree that pet dogs with cancer should be used in early cancer drug trials?

More »